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Abstract
Introduction: Fiducial markers (FMs) are commonly inserted into the prostate
for image guided radiation therapy. This study aimed to quantify prostate
oedema immediately following FM insertion compared to prostate volumes
measured a week later, at the time of simulation for radiation therapy.
Methods: Thirty patients underwent a verification computed tomography
(VCT) scan in treatment position immediately after the fiducial insertion and
their planning computed tomography scan (PCT) one week after. Patient data
sets were retrospectively evaluated, comparing prostate volumes and planning
target volumes (PTV). Volumes were delineated by a single radiation
oncologist, blinded to whether the scan was VCT or PCT. Distances between
the FMs were measured on both scans. Descriptive statistics described the data,
DICE similarity co-efficient (DSC) calculated, and paired t-tests were used to
compare paired data. Results: The median prostate volume was 35.09 cc and
36.31 cc for VCT and PCT data sets, respectively, and median PTV was
118.56 cc and 127.04 cc for VCT and PCT, respectively. There was no
significant difference in prostate volumes (P = 0.3037) or PTV (P = 0.1279),
with a DSC of 0.87 (range 0.76–0.91) and 0.91 (range 0.85 to 0.95),
respectively. Similarly, there was no significant difference in distance between
fiducial markers (P > 0.05). Conclusion: This study demonstrates no
statistically significant difference in prostate or PTV volumes (P > 0.05)
between the CT acquired at fiducial marker insertion compared with the CT
acquired a week later. Therefore, oedema is not significant enough to justify a
delay between FM insertion and simulation.
Introduction
Radiotherapy is one of the most common treatment
options for prostate cancer, the most prevalent cancer
and the second most common cause of death from cancer
in Australian men.1,2 There are two main methods of
delivering radiation: brachytherapy or external beam
radiation therapy (EBRT). Greater accuracy of EBRT has
been achieved with the introduction of image guided
radiotherapy using gold fiducial markers (FMs) to localise
the prostate prior to treatment.3,4 Fiducial marker use has
improved tumour targeting and allowed dose escalation
to safely improve treatment outcomes for prostate cancer
patients.4,5 Brachytherapy is considerably more invasive as
it involves the insertion of approximately 80–100
radioactive seeds (low dose rate brachytherapy) or
multiple hollow catheters (high dose rate brachytherapy)
into the prostate via a transperineal route while the
patient is under anaesthetic. The procedure causes
haemorrhage and oedema, which may cause up to 50%
increase in gland volume.6
Fiducial markers insertion to aid image guided EBRT is
now considered gold-standard practice.4 The procedure is
often performed by urologists or radiologists, while at
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Townsville Cancer Centre, a multidisciplinary radiation
oncology team approach was implemented. The team
comprises a radiation oncologist (RO) to perform the
insertion, a trained radiation therapist to control the
ultrasound machine and a nurse to assist the procedure.
Three FMs are inserted into the prostate gland
transrectally with a 17-gauge needle under ultrasound
guidance and local anaesthetic requiring a minimum of
five needle insertions. During the implementation of
insertions by the ROs, patients underwent a verification
computed tomography (VCT) scan within 30 min of the
insertion procedure in the treatment position to confirm
correct placement of the FMs. Patients had their radiation
therapy planning computed tomography scan (PCT) one
week later. Patients underwent the same CT protocol for
both scans, and 2 mm slice thickness was acquired to
allow for optimal visualisation of the fiducial markers
which are 1 9 3 mm cylinders (CIVCO, Iowa, USA).
Fiducial markers insertion and brachytherapy
procedures both cause prostate oedema. Mechanical
trauma from the needle insertion, intra-prostatic bleeding
and the general inflammatory response can cause the
prostate to swell; this swelling and inflammation can give
an inaccurate representation of true prostate size and
shape.7 Therefore, a delay of at least one week between
FM insertion and treatment simulation is standard to
allow oedema to resolve.4 However, no previous studies
have investigated the magnitude and clinical relevance of
prostate oedema following FM insertion, and thus, the
one week delay may not be required. This study measured
FM-induced prostate swelling by measuring the distance
between the FMs and the prostate volumes on CT scans
both immediately after and one week following insertion.
Method
Design and data
This study was a retrospective audit of CT images to
recalculate prostate volumes. The planning scans of 30
patients selected ad hoc between August 2013 and
December 2014 were re-contoured by the RO.
Participants were included if they had prostate cancer,
were treated using EBRT and had no contraindications
for treatment. Participants were excluded if there were
fewer than three FMs on either scan or if extensive CT
artefacts such as those caused by hip prostheses made
prostate delineation difficult.
Sample size
An initial sample size of 21 patients was calculated, for a
level of significance of 0.05 and power of 80%, detecting
a 5% difference in prostate volume size. To enable the
possibility of parametric tests on potentially
nonparametric data, the sample was increased to a total
of 30.8
Volume and distance measures
The data sets from both the verification and planning CT
scans were deidentified and renamed in the Monaco
planning system (Elekta, Missouri, USA) so that the RO
was blinded to which CT scan they were contouring.
Additionally, the RO contoured each prostate contour
separately on each relevant scan, without reference to any
previous contour, with at least one week between
contouring the previous volume to minimise any prior
knowledge bias. The VCT and PCT were fused, using the
fiducials as points of interest for the registration. To
improve fusion of the two scans, rotational correction
was also used. Where an acceptable fusion could not be
achieved, a ‘best-fit’ fusion was performed and verified by
another investigator. If consensus on an acceptable fusion
could not be reached, the patient was excluded.
One RO contoured the prostate volume and generated
the PTV volumes on both verification and planning scans
for all patients. A conventional PTV expansion of 10 mm
except 5 mm in the posterior direction was applied. The
VCT volumes were then copied to the PCT data set. The
intersect volume, that is the common volume, shared by
both the VCT and PCT contours was generated utilising
the contouring tools within the planning system
(Figure 1). The prostate and PTV volumes, intersect
prostate and intersect PTV volumes were recorded in
cubic millimetres. Utilising these recorded volumes, the
Concordance Index (CI), DICE Similarity Co-efficient
(DSC; Equation 1) and Hausdorff distance were
calculated. The CI is a ratio of the overlap presented as a
percentage.9 The DSC is a measurement of the spatial
similarity of two volumes where 0 indicates no overlap
between the two volumes and one indicates complete
overlap between the two volumes, indicating agreement
between both volume and space.10,11 Both the DSC and
Hausdorff distance were calculated using SlicerRT.12
DICE similarity co-efficient
DSC ¼ 2 A \ Bð Þ
Aþ Bð Þ (1)
where A = volume from VCT, B = volume from PCT,
A \ Bð Þ = intersect of volumes A and B.
For the distance between markers, the coordinates of
the centre of each fiducial marker contour were recorded
for each scan, and the distance between each was
recorded in centimetres.
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Statistical analysis
All data were recorded as numerical values. All data were
collated in a spreadsheet (Microsoft Excel, Microsoft
Corp., Washington, USA) and transferred to R statistical
software version 3.6.1.13 Data were paired and checked
for normality assumptions. Median and interquartile
ranges (IQ range) have been used to describe data, while
paired t-tests were used to compare paired data.
Ethics
Ethics approval was obtained from The Townsville
Hospital and Health Service Human Research Ethics
Committee prior to data mining (HREC/13/QTHS/22).
No patient contact was required for this study.
Results
Patient eligibility and demographics
During the study period, 36 patient data sets were
screened. Five were excluded due to ineligibility. One
patient had hip prosthesis. Three patients had fewer than
three fiducials within the prostate on either scan; one
with a seed placed outside of the prostate on the VCT.
One further patient data set was excluded due to poor
fusion quality, with large differences in pelvic tilt and
surrounding bladder and bowel filling causing some
potential prostate deformation.
Of the 30 patients, 23 (76%) were on hormone therapy
for a median of 92 days prior to the VCT (range 0–
353 days). Median age was 71 years (range: 57–81). No
further demographics were collected on participants.
Individual patient data are presented in Table 1.
Median planning verification and planning
volumes
Median prostate and target volume measured at the
verification scans were 35.09 cc (IQ range 27.77–50.07 cc)
and 118.56 cc (IQ range 104.02–157.09 cc), respectively.
A week later at the planning scan, the volumes for the
prostate and target volumes were 36.31 cc (IQ range
27.34–55.12 cc) and 127.04 cc (IQ range 103.78–
160.15 cc), respectively (Figure 2). Comparison between
verification and planning scans show no significant
difference for the prostate volumes (P = 0.30) or
planning target volumes (0.13) (Table 2).
Median DICE similarity co-efficient
The median DSC between the verification and planning
volumes for the prostate volumes was 0.87. The median
DSC between the verification and planning volumes for
the target volume was 0.91 (Table 2).
Figure 1. Example of PTV volumes assessed.VCT (blue) and PCT (magenta) PTV volumes as contoured by the RO, and volume intersect (purple)
as generated by the planning system.
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Hausdorff distance measures
The median Hausdorff distance between the verification
and planning volumes for the prostate volumes was
1.69 mm. The median Hausdorff distance between the
verification and planning volumes for the target volume
was 1.76 mm (Table 2).
Median differences between fiducial
markers
There was no significant difference in the distances
between fiducial markers (Table 3). The median distance
between fiducial markers 1 and 2 at verification was
2.45 cm, and at the planning scan, it was 2.39 cm. The
median distance between fiducial markers 2 and 3 at
verification was 1.39 cm, and at planning scan, it was
1.42 cm. The median distance between fiducial markers 1
and 3 at the verification was 2.38 cm, and at planning
scan, it was 2.35 cm.
Discussion
This study demonstrates that there is no significant
change in prostate size or shape between the VCT and
PCT and confirms that the delay between FM insertion
and CT simulation is unnecessary. Until this study, our
departmental protocol of mandating a one-week delay
between gold seed insertion and radiotherapy planning
was consistent with the Royal Australian and New
Zealand College of Radiologists’ (RANZCR)
recommendations.4 A recent survey of 15 radiotherapy
centres in the United Kingdom reported that all centres
wait at least one week between insertion and CT
simulation.14 However, prostate oedema literature
predominantly addresses oedema following brachytherapy,
which is significantly more invasive than FM insertion,
with no studies specifically investigating the degree or
significance of oedema following FM insertion.
The magnitude of brachytherapy-induced prostate
oedema is best determined by measuring the prostate
volume pre- and post-insertion. A variety of prostate
volume increases have been observed ranging from 10 to
43%.6,15,16 However, the significant prostate volume
changes seen after brachytherapy may not be seen after
FM insertion because of the difference in the number of
needle insertions and seeds. A limitation of our study is
that there is no pre-implant scan to measure the direct
magnitude of oedema caused by insertion.
Nichol et al compared prostate volumes by measuring
pre-insertion prostate volumes calculated on ultrasound
and comparing to MRI delineated volumes on the day of
CT simulation, with a median of 6 days between the
two.17 The MRI volume was 3.5 mL larger than on US
(P = 0.006); however, this is attributed to the different
Figure 2. Boxplot of prostate (A) and PTV volumes (B), comparing
verification and planning scans.
Table 2. Comparison between VCT and PCT prostate and target volumes.






Prostate VCT 35.09 16.23–81.77 27.77–50.07 0.3037 0.87 (0.76–0.91) 1.69 (0.74–2.25) 6.53 (4.14–10.47)
Prostate PCT 36.31 15.84–89.69 27.34–55.12
Planning target VCT 118.56 76.21–221.82 104.02–157.09 0.1279 0.91 (0.85–0.95) 1.76 (0.80–2.46) 6.53 (3.79–10.47)
Planning target PCT 127.04 73.57–239.11 103.78–160.15
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imaging modalities rather than insertion-induced oedema.
Our study compares the prostate volumes and fiducial
marker coordinates using the same imaging technique
across both measurements.
This study demonstrated no difference in the clinically
relevant measurements between verification and planning
scans. The lack of significant difference between the
prostate volumes, target volumes or the distances between
fiducial markers demonstrates no significant oedema
immediately after the procedure. Therefore, CT
simulation could be performed on the same day as
implantation.
Migration of fiducial markers has been a reported issue
in the literature.18 We noted that three patients lost a
seed between VCT and PCT. While these were excluded
for the purposes of this study, IGRT was still able to be
performed with the remaining two seeds in conjunction
with checking soft tissue on daily cone-beam CT (CBCT).
Migration of FMs during the treatment course itself has
not been noted within our institution, suggesting
suboptimal FM insertion will have the greatest impact
between simulation and treatment commencement.
Therefore, departments should have a workflow to
address this, such as using a combination of FMs and
CBCT.
All but two patients who were on hormones were so
for greater than 50 days prior to VCT; therefore, we
assume the hormones had little further effect on prostate
volume in the week between the two scans.
There was some contour edge variation evident in the
Hausdorff distances recorded, upon visual inspection,
these were largely at the base of the prostate, where
differences particularly in bladder volumes impacted the
prostate deformation and definition. Edge variability for
the prostate has potential for clinical ramifications;
however, this is largely mitigated by PTV margin
expansions. The lowest prostate CI (73.95%) and DSC
(0.76) and maximum prostate Hausdorff distances
(10.47 mm) were observed in the same patient data set
(Patient 9). We examined this patient’s scans and noted
that the prostate was particularly difficult to fuse and
delineate in both scans. Of note is the PTV expansion
DSC of 0.86 and CI of 86.8% demonstrated some
expansion mitigation in this case. As noted, conventional
CTV-PTV expansions of 10 mm except 5 mm in the
posterior were used as per standard clinical practice;
however, further consideration should be given to
reduced margin expansion.
Difficulties in prostate delineation on CT alone are well
recognised, with reported inter- and intra-observer
differences.19–21 These known difficulties in contouring
on CT suggest this study could be repeated with other
imaging modalities, such as MRI. However, MRI involves
other considerations such as the local signal void of FMs
on MR, introducing another potential limitation. 22
Additionally, timely access to MRI machines can be
limited.
It is also recognised that individual patient factors may
contribute to the rate of oedema, such as tissue perfusion
and blood flow.23,24 Taussky et al reported an association
with smaller prostate sizes and greater oedema in the
brachytherapy setting; however, this was not found in our
cohort.24
In a simulated dosimetric study investigating the
impact of prostate contouring variability, significant
correlations were reported between volume similarity and
PTV dosimetry.25 Further study into dosimetric impacts
and treatment outcomes following implementation of
same-day FM implantation and CT simulation is
recommended.
Radiation therapy CT simulation on the same day as
fiducial marker insertion is of significant benefit to
patients. Benefits include no additional CT appointment
which saves the costs associated with travel, particularly
for patients travelling from rural and regional centres,
potential loss of wages, and is more convenient for the
Table 3. Fiducial marker distance between VCT and PCT scans.
Fiducial marker measurement1 Median (cm) Range IQR P-Value
FM1-FM2 VCT 2.45 0.9–4.2 2.02–2.67 0.843
FM1-FM2 PCT 2.39 0.83–3.98 1.96–2.66
FM1-FM2 difference 0.01 0.26–0.10 0.09–0.02
FM2-FM3 VCT 1.39 0.31–2.84 1.13–1.59 0.839
FM2-FM3 PCT 1.42 0.5–2.79 1.22–1.59
FM2-FM3 difference 0.02 0.18–0.23 0.06–0.10
FM3-FM1 VCT 2.38 1.28–4.21 2.11–2.82 0.895
FM3-FM1 PCT 2.35 1.23–4.25 2.03–2.79
FM3-FM1 difference 0.02 0.2–0.18 0.09–0.03
1
Difference: PCT fiducial marker position minus VCT fiducial marker position.
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patient and their family/carers. Similarly, the organisation
benefits from an increased appointment capacity. It is
recognised that other logistical issues may arise if
insertion is being performed within another department
or clinic, such as urology or radiology.
Conclusion
This study demonstrated no statistical difference in
prostate or PTV volumes (P > 0.05) between a CT
acquired at fiducial marker insertion compared with a CT
acquired a week later and thus suggests there is no
significant oedema to justify imposing a delay between
FM insertion and CT simulation.
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